STAT3 and hematologic disorder: However, early-phase clinical trials with drugs targeting STAT3 are ongoing in solid and hematologic malignancies other than LGLL, namely AZD9150, a STAT3 antisense oligonucleotide, and Napabucasin, an inhibitor of gene expression driven by STAT3 (56).